Brad Canino
Stock Analyst at Guggenheim
(3.75)
# 759
Out of 5,031 analysts
16
Total ratings
61.54%
Success rate
9.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brad Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGON CG Oncology | Initiates: Buy | $90 | $41.46 | +117.08% | 1 | Oct 8, 2025 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $20 | $9.36 | +113.68% | 1 | Oct 8, 2025 | |
| CELC Celcuity | Initiates: Buy | $110 | $51.96 | +111.70% | 1 | Sep 22, 2025 | |
| ORIC ORIC Pharmaceuticals | Assumes: Buy | $18 | $12.78 | +40.85% | 1 | Sep 4, 2025 | |
| RLAY Relay Therapeutics | Assumes: Buy | $15 | $6.49 | +131.12% | 1 | Sep 4, 2025 | |
| NUVL Nuvalent | Assumes: Buy | $122 | $92.52 | +31.86% | 1 | Sep 4, 2025 | |
| CCCC C4 Therapeutics | Initiates: Buy | $8 | $2.37 | +237.55% | 1 | Sep 4, 2025 | |
| JANX Janux Therapeutics | Initiates: Buy | $72 | $26.76 | +169.06% | 1 | Sep 4, 2025 | |
| KURA Kura Oncology | Initiates: Neutral | n/a | $9.84 | - | 1 | Sep 4, 2025 | |
| BDTX Black Diamond Therapeutics | Initiates: Buy | $8 | $4.01 | +99.50% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $20.99 | +90.57% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $3.36 | +48.81% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $450 | $9.88 | +4,454.66% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $18.40 | +198.91% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $39.25 | -23.57% | 2 | Mar 31, 2021 |
CG Oncology
Oct 8, 2025
Initiates: Buy
Price Target: $90
Current: $41.46
Upside: +117.08%
Olema Pharmaceuticals
Oct 8, 2025
Initiates: Buy
Price Target: $20
Current: $9.36
Upside: +113.68%
Celcuity
Sep 22, 2025
Initiates: Buy
Price Target: $110
Current: $51.96
Upside: +111.70%
ORIC Pharmaceuticals
Sep 4, 2025
Assumes: Buy
Price Target: $18
Current: $12.78
Upside: +40.85%
Relay Therapeutics
Sep 4, 2025
Assumes: Buy
Price Target: $15
Current: $6.49
Upside: +131.12%
Nuvalent
Sep 4, 2025
Assumes: Buy
Price Target: $122
Current: $92.52
Upside: +31.86%
C4 Therapeutics
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $2.37
Upside: +237.55%
Janux Therapeutics
Sep 4, 2025
Initiates: Buy
Price Target: $72
Current: $26.76
Upside: +169.06%
Kura Oncology
Sep 4, 2025
Initiates: Neutral
Price Target: n/a
Current: $9.84
Upside: -
Black Diamond Therapeutics
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $4.01
Upside: +99.50%
Sep 4, 2025
Initiates: Buy
Price Target: $40
Current: $20.99
Upside: +90.57%
Sep 4, 2025
Initiates: Buy
Price Target: $5
Current: $3.36
Upside: +48.81%
Mar 31, 2021
Initiates: Neutral
Price Target: $450
Current: $9.88
Upside: +4,454.66%
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $18.40
Upside: +198.91%
Mar 31, 2021
Initiates: Outperform
Price Target: $30
Current: $39.25
Upside: -23.57%